BONI LUCA CURRICULUM

Europass
Curriculum Vitae
Personal information
First name(s) / Surname(s)
Nationality
Luca Boni
Italian
Desired employment / Clinical epidemiology, biostatistics
Occupational field
Work experience
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Type of business or sector
Dates
Occupation or position held
Main activities and responsibilities
Page 1 / 12 - Curriculum vitae of
Luca Boni
1 Sep 08 – present
Head of Clinical Trials Coordinating Center of Istituto Toscano Tumori (ITT)
Senior Biostatistician
Visiting professor at the University of Florence
President of the Patents Committee of AOU Careggi, Florence
Member of the Institutional Review Board of AOU Careggi, Florence
Provide statistical leadership for clinical trials and observational studies
Give an operative support for the planning, conducting and statistical analysis of results of
investigator-initiated clinical trials and observational studies
Guarantee the quality of data and statistical integrity of the clinical studies
Promote the partnership between the ITT network and other Institutions or Cooperative Research
Groups
Supervise the Clinical Research Administrators operating within the ITT network and interacting
with the Health Authorities
Supervise the Statisticians operating within the ITT network
Supervise the Programmers during the clinical database design process
Communicate results to non-statistical audience
Contribute to the scientific paper writing process
Facilitate the spread of the knowledge about clinical epidemiology methodologies
Represent a consulting reference point for the Scientific Board of ITT, in matter of clinical research
Collaborate with the Regional Health System for facilitating the spread of research activities within
the Public Institutions and promoting operative synergisms with the Drug Companies
Manage the annual economical budget and promote the fundraising task
AOU Careggi / Istituto Toscano Tumori
L.go Brambilla 3, 50134 Firenze (Italy)
Clinical research
1 May 03 - 31 Aug 08
Head of Clinical Trials Unit of Istituto Nazionale per la Ricerca sul Cancro (IST)
Senior Biostatistician
Member of the Scientific Review Board of IST, Genoa
Provide statistical leadership for clinical trials and observational studies
November, 2014
Promote the collaboration between the investigators of the Institute and the Drug Companies
Give an operative support for the planning, conducting and statistical analysis of results of
investigator-initiated clinical trials and observational studies
Guarantee the quality of data and statistical integrity of the clinical studies
Supervise the Data Managers operating within the Unit
Supervise the Programmers during the clinical database design process
Communicate results to non-statistical audience
Contribute to the scientific paper writing process
Manage the annual economical budget and promote the fundraising task
Name and address of employer
Type of business or sector
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Type of business or sector
Istituto Nazionale per la Ricerca sul Cancro di Genova
L.go Rosanna Benzi 10, 16132 Genova (Italy)
Clinical research
1 May 98 - 31 Jan 03
Head of Clinical Trials Unit of Associazione Biomedical Technology Assessment (BETA).
Biostatistician.
Provide statistical leadership for clinical trials and observational studies
Promote the collaboration between the investigators of the Institute and the Drug Companies
Give an operative support for the planning, conducting and statistical analysis of results of profit
and non-profit clinical trials and observational studies
Guarantee the quality of data and statistical integrity of the clinical studies
Supervise the Data Managers operating within the Unit
Supervise the Programmers during the clinical database design process
Communicate results to non-statistical audience
Contribute to the scientific paper writing process
Manage the annual economical budget and promote the fundraising task
Associazione Biomedical Technology Assessment (BETA)
L.go Rosanna Benzi 10, 16132 Genova (Italy)
Clinical research
Dates
1 Mar 93 - 30 Apr 98
Occupation or position held
Research fellow
Junior Biostatistician
Main activities and responsibilities
Name and address of employer
Type of business or sector
Dates
Occupation or position held
Main activities and responsibilities
Name and address of employer
Type of business or sector
Collaborate with the Senior Statistician
Give an operative support for the planning, conducting and statistical analysis of results of profit
and non-profit clinical trials and observational studies
Guarantee the quality of data and statistical integrity of the clinical studies
Communicate results to non-statistical audience
Contribute to the scientific paper writing process
Istituto Nazionale per la Ricerca sul Cancro di Genova
L.go Rosanna Benzi, 16132 Genova (Italy)
Clinical research
1 Dec 86 - 30 Apr 92
Research fellow
Design, management and reporting of observational studies
Istituto Giannina Gaslini
L.go Gerolamo Gaslini 5, 16147 Genova (Italy)
Clinical research
Education and training
Dates
Title of qualification awarded
Name and type of organisation
providing education and training
Page 2 / 12 - Curriculum vitae of
Luca Boni
Jul 03
Postgraduate degree in Biostatistics
Università degli Studi di Milano (University)
Via Festa del Perdono 7, 20122 Milano (Italy)
November, 2014
Dates
Title of qualification awarded
Name and type of organisation
providing education and training
Oct 93
Degree in Medicine and Surgery
Università degli Studi di Genova (University)
Via Balbi 5, 16126 Genova (Italy)
Personal skills and
competences
Mother tongue(s)
Italian
Other language(s)
Self-assessment
European level (*)
English
Understanding
Listening
B1 Independent user C1
Reading
Proficient user
Speaking
Spoken interaction
Writing
Spoken production
B2 Independent user B2 Independent user C1
Proficient user
(*) Common European Framework of Reference (CEF) level
Social skills and competences
Good abilities for synthetic and global views over concrete situations
Problem-solving attitude
Ability to establish and maintain good working relations with people of different national and cultural
backgrounds
Good communication skills gained through my experience as teaching professor
Organisational skills and competences
Leadership (in different times and situations responsible for a team of 10 people)
Sense of organisation
Good experience in project or team management
Excellent analytical skills and strong attention to details
Ability to work independently
Technical skills and competences
Excellent ability in the design and protocol writing of clinical trials and observational studies
Great experience in statistical analysis in a clinically related subjects, such as clinical trials,
epidemiological studies and outcomes research, in collaboration with non-profit and profit entities,
such as Academic Departments and Pharmaceutical Companies (Eli Lilly, Roche, Novartis, Celgine,
Sanofi Aventis, Bristol Meyer Squibb)
Extensive knowledge of the methodological issues related to different fields of clinical research, such
as oncology, cardiology, infectivology, andrology, neurology, diabetology, haematology, radiology,
general surgery.
Thorough understanding of statistical issues in clinical studies (interventional and non-interventional)
Great practical experience with SAS programming
Excellent experience in the conduction of clinical researches, in accordance with the ICH and GCP
regulations and guidelines
Excellent ability and experience in the statistical analyses of results, data interpretation and scientific
paper writing
High teaching and scientific writing experience
Excellent knowledge of data-management procedures (data tracking, quality assurance)
High experience about the planning, writing and management of Standard Operative Procedures
Computer skills and competences
Excellent computer proficiency
Editing: MS Word, MS PowerPoint
Databases: MS Access, MSSql, MySql
Statistical packages: SAS, R, Stata, SPSS, BMDP, S-Plus, GLIM, Epicure
Programming languages: php, JavaScript, Html, Basic, Pascal
Page 3 / 12 - Curriculum vitae of
Luca Boni
November, 2014
Development of web-based applications (developer of a patients registration/randomization and
remote data-entry system)
Artistic skills and competences
Driving licence(s)
Good knowledge of photography technique and composition
B
Annexes Annex A - List of selected scientific pubblications
Firenze, November 3rd, 2014
Page 4 / 12 - Curriculum vitae of
Luca Boni
November, 2014
ANNEX A - LIST OF SELECTED SCIENTIFIC PUBBLICATIONS
■
Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G,
Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
N Engl J Med. 2014 Oct 23;371(17):1609-18
■
Tiseo M, Buti S, Boni L, Mattioni R, Ardizzoni A
Prognostic Role of Hyponatremia in 564 Small Cell Lung Cancer Patients Treated with Topotecan.
Lung Cancer, in press
■
Ardizzoni A, Tiseo M, Boni L
Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: A pooled analysis of topotecan second-line
trials.
Eur J Cancer. 2014 Jun 26 [Epub ahead of print]
■
Lastraioli E, Boni L, Romoli MR, Crescioli S, Taddei A, Beghelli S, Tomezzoli A, Vindigni C, Saragoni L, Messerini L, Bernini M, Bencini L,
Giommoni E, Freschi G, Di Costanzo F, Scarpa A, Morgagni P, Farsi M, Roviello F, De Manzoni G, Bechi P, Arcangeli A; Gruppo Italiano di
Ricerca Cancro Gastrico (GIRCG)
VEGF-A clinical significance in gastric cancers: Immunohistochemical analysis of a wide Italian cohort.
Eur J Surg Oncol. 2014 Apr 12 [Epub ahead of print]
■
Spirito P, Autore C, Formisano F, Assenza GE, Biagini E, Haas TS, Bongioanni S, Semsarian C, Devoto E, Musumeci B, Lai F, Yeates L,
Conte MR, Rapezzi C, Boni L, Maron BJ.
Risk of sudden death and outcome in patients with hypertrophic cardiomyopathy with benign presentation and without risk factors.
Am J Cardiol. 2014 May 1;113(9):1550-5
■
Crociani O, Lastraioli E, Boni L, Pillozzi S, Romoli MR, D'Amico M, Stefanini M, Crescioli S, Taddei A, Bencini L, Bernini M, Farsi M, Beghelli
S, Scarpa A, Messerini L, Tomezzoli A, Vindigni C, Morgagni P, Saragoni L, Giommoni E, Gasperoni S, Dicostanzo F, Roviello F,
Demanzoni G, Bechi P, Arcangeli A
hERG1 channels regulate VEGF-A secretion in human gastric cancer: clinicopathologial correlations and therapeutical implications
Clin Cancer Res. 2014 Mar 15;20(6):1502-12
■
Inghilesi AL, Gallori D, Antonuzzo L, Forte P, Tomcikova D, Arena U, Colagrande S, Pradella S, Fani B, Gianni E, Boni L, Laffi G, Di
Costanzo F, Marra F
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
World J Gastroenterol. 2014 Jan 21;20(3):786-94
■
Fortunato A, Gasparoli L, Falsini S, Boni L, Arcangeli A
An analytical method for the quantification of hERG1 channel gene expression in human colorectal cancer
Diagn Mol Pathol. 2013 Dec; 22(4):215-21
■
Mazzoni F, Cecere FL, Meoni G, Giuliani C, Boni L, Camerini A, Lucchesi S, Martella F, Amoroso D, Lucherini E, Torricelli F, Di Costanzo F
Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung
cancer
Lung Cancer. 2013 Nov; 82(2):288-93
■
Tiseo M, Bordi P, Bortesi B, Boni L, Boni C, Baldini E, Grossi F, Recchia F, Zanelli F, Fontanini G, Naldi N, Campanini N, Azzoni C, Bordi C,
Ardizzoni A
ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without
cisplatin
Br J Cancer. 2013 Apr 30;108(8):1695-703
■
Arcangeli A, Romoli MR, Boni L, Gerlini G, Tofani L, Urso C, Borgognoni L
High hERG1 expression in advanced melanoma.
Melanoma Res. 2013 Jun;23(3):185-190
■
Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NA 3rd, Shannon KM, Ashley EA, Day SM, Pacileo G, Formisano F,
Devoto E, Anastasakis A, Bos JM, Woo A, Autore C, Pass RH, Boriani G, Garberich RF, Almquist AK, Russell MW, Boni L, Berger S, Maron
MS, Link MS
Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic
cardiomyopathy.
J Am Coll Cardiol. 2013 Apr 9;61(14):1527-35
Page 5 / 12 - Curriculum vitae of
Luca Boni
November, 2014
■
Dani C, Lista G, Pratesi S, Boni L, Agosti M, Biban P, Del Vecchio A, Gazzolo D, Gizzi C, Magaldi R, Messner H, Mosca F, Sandri F,
Scopesi F, Trevisanuto D, Vento G
Sustained lung inflation in the delivery room in preterm infants at high risk of respiratory distress syndrome (SLI STUDY): study protocol for
a randomized controlled trial.
Trials. 2013 Mar 8;14:67
■
Rondelli T, Berardi M, Peruzzi B, Boni L, Caporale R, Dolara P, Notaro R, Luzzatto L
The frequency of granulocytes with spontaneous mutations: a wide distribution in a normal human population.
PlosOne. 2013:8(1):e54046
■
Biganzoli L, Boni L, Becheri D, Zafarana E, Biagioni C, Cappadona S; Bianchini E, Oakman E, Magnolfi SU, Di Leo A, Mottino G
Evaluation of the cardiovascular health study (CHS) instrument and the Vulnerable Elders Survey-13 (VES-13) in elderly cancer patients.
Are we still missing the right screening tool?
Annals of Oncology. 2012 Oct 7 [Epub ahead of print]
■
Ardizzoni A, Tiseo M, Boni L, Vincent AD, Passalacqua R, Buti S, Amoroso D, Camerini A, Labianca R, Amadori D, Boni C, Ciuffreda L, Di
Costanzo F, de Marinis F, Crinò L, Santo A, Pazzola A, Barbieri F, Zilembo N, Merlano M, Tibaldi C, Mattioli R, Cafferata MA, Camisa R,
Russo F and Smit EF
Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer (NSCLC): results of
GOIRC 02-2006 randomized phase II study and pooled analysis with NVALT7 trial.
J Clin Oncol. 2012 Oct 29 [Epub ahead of print]
■
Iacovoni A, Spirito P, Simon C, Iascone M, Di Dedda G, De Filippo P, Pentiricci S, Boni L, Senni M, Gavazzi A, Ferrazzi P
A contemporary European experience with surgical septal myectomy in hypertrophic cardiomyopathy.
Eur Heart J. 2012 Apr 20 [Epub ahead of print]
■
Lastraioli E, Bencini L, Bianchini E, Romoli MR, Crociani O, Giommoni E, Messerini L, Gasperoni S, Moretti R, Di Costanzo F, Boni L,
Arcangeli A
hERG1 channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II Colorectal Cancer: a pilot study.
Transl Oncol. 2012 Apr; 5(2):105-12.
■
Boni C, Tiseo M, Boni L, Baldini E, Recchia F, Barone C, Grossi F, Germano D, Matano E, Marini G, Labianca R, Di Costanzo F, Bagnulo A,
Pennucci C, Caroti C, Mencoboni M, Zanelli F, Prochilo T, Cafferata MA, Ardizzoni A
Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a
multicenter randomised factorial trial (FAST).
Br J Cancer. 2012 Jan 12. doi: 10.1038/bjc.2011.606. [Epub ahead of print] PubMed PMID: 22240782.
■
Grossi F, de Marinis F, Gebbia V, Riccardi F, Caffo O, Gamucci T, Ferraù F, Nardi M, Moscetti L, Boni L, Dondi D, Galligioni E
A randomised phase II trial of two sequential schedules of docetaxel and cisplatin followed by gemcitabine in patients with advanced nonsmall-cell lung cancer.
Cancer Chemother Pharmacol. 2011 Jul 21. [Epub ahead of print] PubMed PMID: 21833588.
■
Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, Giordano M, Garrone O, Pronzato P, Bighin C, Levaggi A, Giraudi S, Cresti
N, Magnolfi E, Scotto T, Vecchio C, Venturini M
Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in
premenopausal women with breast cancer: a randomized trial.
JAMA. 2011 Jul 20;306(3):269-76. PubMed PMID: 21771987.
■
Mazzoni F, Rotella V, Pratesi N, Boni L, Simi L, Orlando C, Comin CE, Maddau C, Di Costanzo F
From clinical trials to clinical practice: predictors of response to erlotinib in advanced non-small cell lung cancer patients pretreated with
chemotherapy.
Tumori. 2011 Mar-Apr;97(2):160-5.
■
Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, Artale S, Tagliagambe A, Ambrosini G, Rosetti P, Bonetti A, Negru ME,
Tronconi MC, Luppi G, Silvano G, Corsi DC, Bochicchio AM, Chiaulon G, Gallo M, Boni L
Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the
STAR-01 randomized phase III trial.
J Clin Oncol. 2011 Jul 10;29(20):2773-80. Epub 2011 May 23.
Page 6 / 12 - Curriculum vitae of
Luca Boni
November, 2014
■
Rubie H, De Bernardi B, Gerrard M, Canete A, Ladenstein R, Couturier J, Ambros P, Munzer C, Pearson AD, Garaventa A, Brock P, Castel
V, Valteau-Couanet D, Holmes K, Di Cataldo A, Brichard B, Mosseri V, Marquez C, Plantaz D, Boni L, Michon J.
Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification:
results of the prospective INES 99.1.
J Clin Oncol. 2011 Feb 1;29(4):449-55. Epub 2010 Dec 20.
■
Mikulska M, Del Bono V, Prinapori R, Boni L, Raiola AM, Gualandi F, Van Lint MT, Dominietto A, Lamparelli T, Cappellano P, Bacigalupo A,
Viscoli C
Risk factors for enterococcal bacteremia in allogeneic hematopoietic stem cell transplant recipients.
Transpl Infect Dis. 2010 Jul 15. [Epub ahead of print]
■
Biagini E, Spirito P, Rocchi G, Ferlito M, Rosmini S, Lai F, Lorenzini M, Terzi F, Bacchi-Reggiani L, Boriani G, Branzi A, Boni L, Rappezzi C.
Prognostic implications of the Doppler restrictive filling pattern in hypertrophic cardiomyopathy.
Am J Card, 2009 Dec 15; 104(12); 1727:1731.
■
Regge D, Laudi C, Galatola G, Della Monica P, Bonelli L, Angelelli G, Asnaghi R, Barbaro B, Bartolozzi C, Bielen D, Boni L, Borghi C, Bruzzi
P, Cassinis MC, Galia M, Gallo TM, Grasso A, Hassan C, Laghi A, Martina MC, Neri E, Senore C, Simonetti G, Venturini S, Gandini G.
Diagnostic accuracy of computed tomographic colonography for the detection of advanced neoplasia in individuals at increased risk of
colorectal cancer.
JAMA. 2009 Jun 17;301(23):2453-61.
■
Tiseo M, Rossi G, Capelletti M, Sartori G, Spiritelli E, Marchioni A, Bozzetti C, De Palma G, Lagrasta C, Campanini N, Camisa R, Boni L,
Franciosi V, Rindi G, Ardizzoni A.
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): Study of a comprehensive panel of molecular markers.
Lung Cancer. Epub 2009 May 25; 2010 Mar; 67(3); 355-360.
■
De Bernardi B, Gerrard M, Boni L, Rubie H, Cañete A, Di Cataldo A, Castel V, Forjaz de Lacerda A, Ladenstein R, Ruud E, Brichard B,
Couturier J, Ellershaw C, Munzer C, Bruzzi P, Michon J, Pearson AD.
Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification.
J Clin Oncol. 2009 Mar 1;27(7):1034-40.
■
Leoncini G, Iurilli L, Boni L, Blanco G, De Bellis P, Catrambone G.
Treatment of iatrogenic and traumatic tracheal disruptions.
Monaldi Arch Chest Dis. 2008 Sep;69(3):119-27.
■
Tiseo M, Capelletti M, De Palma G, Franciosi V, Cavazzoni A, Mozzoni P, Alfieri RR, Goldoni M, Galetti M, Bortesi B, Bozzetti C, Loprevite
M, Boni L, Camisa R, Rindi G, Petronini PG, Ardizzoni A.
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
J Thorac Oncol. 2008 Oct;3(10):1104-11.
■
Catania G, Poirè I, Dozin B, Bernardi M, Boni L.
Validating a measure to delineate the clinical trials nursing role in Italy.
Cancer Nurs. 2008 Sep-Oct;31(5):E11-5.
■
Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, Radosavljevic D, Paccagnella A, Zatloukal P, Mazzanti P, Bisset D,
Rosell R
Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data
meta-analysis.
J Natl Cancer Inst. 2007 Jun 6;99(11):847-57.
■
Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S.
Metabolic Treatment with L-Carnitine in Acute Anterior ST Segment Elevation Myocardial Infarction. A Randomized Controlled Trial.
Cardiology. 2006;106(4):215-23. Epub 2006 May 9.
■
Catania G, Costantini M, Lambert A, Luzzani M, Marceca F, Tridello G, Boni L, Bernardi M.
[Testing an instrument measuring Italian nurses' knowledge and attitudes regarding pain]
Assist Inferm Ric. 2006 Jul-Sep;25(3):149-56. Italian.
■
Benasso M, Ponzanelli A, Merlano M, Numico G, Ricci I, Vigo V, Grossi F, Amadori D, Cavallo G, Capaccetti B, Taveggia P, Boni L, Rosso
R.
Paclitaxel, cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck: a phase II trial from an Italian cooperative
group.
Acta Oncol. 45(2):168-74, 2006.
Page 7 / 12 - Curriculum vitae of
Luca Boni
November, 2014
■
Miglietta L, Franzone P, Centurioni MG, Boni L et al.
A phase II trial with cisplatin/paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or
recurrent cervical cancer.
Oncology 70:19-24, 2006.
■
Del Mastro L, Catzeddu T, Boni L, Bell C, Sertoli MR, Bighin C, Clavarezza M, Testa D, Venturini M.
Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.
Ann Oncol. 17(1):74-8, 2006.
■
Tiseo M, Boni L, Ardizzoni A.
Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a
difference ?
J Clin Oncol. 23(25):6276-7, 2005.
■
London WB, Boni L, Simon T, Berthold F, Twist C, Schmidt ML, Castleberry RP, Matthay KK, Cohn SL, De Bernardi B.
The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives.
Cancer Lett. 228(1-2):257-66, 2005.
■
Lanciotti M, Coco S, Michele PD, Haupt R, Boni L et al.
Glutathione S-transferase polymorphisms and susceptibility to neuroblastoma.
Pharmacogenet Genomics, 15(6):423-426, 2005.
■
Ardizzoni A, Favaretto A, Boni L et al.
Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study
assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and
Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
J Clin Oncol., 23(3):569-75, 2005.
■
Grossi F, Loprevite M, Chiaramondia M, Ceppa P, Pera C, Ratto GB, Serrano J, Ferrara GB, Costa R, Boni L, Ardizzoni A.
Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
Eur J Cancer, 39(9):1242-50, 2003.
■
Garaventa A, Luksch R, Lo Piccolo MS, Cavadini E, Montaldo PG, Pizzitola MR, Boni L et al.
Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.
Clin Cancer Res., 9(6):2032-9, 2003.
■
Romani M, Tonini GP, Banelli B, Alemanni G, Mazzocco K, Scaruffi P, Boni L et al.
Biological and clinical role of p73 in neuroblastoma.
Cancer Lett., 18, 197(1-2):111-7, 2003. Review.
■
Costantini M, Higginson IJ, Boni L et al.
Effect of a palliative home care team on hospital admissions among patients with advanced cancer.
Palliative Medicine, 17, 315-321, 2003.
■
Castagnola E, Boni L, Giacchino M et al.
A multicenter, randomized, double blind placebo - controlled trial of amoxicillin / clavulanate for the prophylaxis of fever and infection in
neutropenic children with cancer.
Pediatr Infect Dis J., 22(4), 359-365, 2003.
■
De Bernardi B, Nicolas B, Boni L et al.
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols
adopted by the italian co-operative group for neuroblastoma (ICGNB).
J Clin Oncol., 21(8), 1592-1601, 2003.
■
Gambini C, Sementa AR, Boni L et al.
Expression of HER2/neu is uncommon in human neuroblastic tumors and is unrelated to tumor progression
Cancer Immunol Immunother., 52(2), 116-120, 2003.
■
Garaventa A, Boni L, Lo Piccolo MS et al.
Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors.
Annals of Oncology, 13, 956-964, 2002
Page 8 / 12 - Curriculum vitae of
Luca Boni
November, 2014
■
Casciano I, Mazzocco K, Boni L et al.
Expression of DNp73 is a molecular marker for adverse outcome in neuroblastoma patients.
Cell Death and Differentiation, 9, 246-251, 2002
■
Baldini E, Ardizzoni A, Prochilo T, Cafferata M, Boni L, Tibaldi C, Neumaier C, Conte P, Rosso R
Gemcitabine, ifosfamide and navelbine (GIN): activity and safety of a non platinum based triplet in advanced non small cell lung cancer
(NSCLC).
Br. J. Cancer, 85, 1452-1455, 2001
■
Pietra G, Semino C, Cagnoni F, Boni L, Cangemi G, Frumento G, Melioli G
Natural killer cells lyse autologous herpes simplex virus infected targets using cytolytic mechanisms distributed clonotypically.
J. Med. Virol., 62, 354-363, 2000
■
Marangelli V, Memmola C, Brigiani MS, Boni L et al.
Early administration of verapamil after thrombolysis in acute anterior myocardial infarction. Effect on left ventricular remodeling and clinical
outcome. Vami Study Group.
Ital Heart J, 1(5):336-343, 2000
■
Ardizzoni A, Antonelli G, Ricci S, Frasci G, Rinaldi M, Boni L et al.
Ambamustine in the second-line treatment of patients with small-cell lung cancer.
Am J Clin Oncol 23(1):22-25, 2000
■
Ardizzoni A, Grossi F, Scolaro T, Giudici S, Foppiano F, Boni L et al.
Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small cell lung
cancer.
Br J Cancer, 81(2):310-315, 1999
■
Romani M, Scaruffi P, Casciano I, Mazzocco K, Lo Cunsolo C, Cavazzana A, Gambini C, Boni L et al.
Stage-independent expression and genetic analysis of tp73 in neuroblastoma.
Int J Cancer, 30;84(4):369-369, 1999
■
Menozzi C, Brignole M, Alboni P, Boni L et al.
The natural course of untreated sick sinus syndrome and identification of the variables predictive of unfavorable outcome.
Am J Cardiol, 82:1205-1209, 1998
■
Iolascon A, Lo Cunsolo C, Giordani L, Cusano R, Mazzocco K, Boumgartner M, Ghisellini P, Faienza MF, Boni L et al.
Interstitial and large chromosome 1p deletion occurs in localized and disseminated neuroblastomas and predicts an unfavourable outcome.
Cancer Letters, 130:83-92, 1998
■
Giacchino R, Marazzi MG, Barabino A, Fasce L, Ciravegna B, Famularo L, Boni L, Callea F
Syndromic variability of Wilson's disease in children. Clinical study of 44 cases.
Ital J Gastroenterol Hepatol, 29:155-161, 1997
■
Colleoni M, Liessi G, Mastrapasqua G, Boni L et al.
Prognostic factors in patients with hepatocellular carcinoma submitted to chemoembolization.
Oncology Reports, 4:1025-1028, 1997
■
Sciallero S, Costantini M, Bertinelli E, Castiglione G, Onofri P, Aste H, Casetti T, Mantellini P, Bucchi L, Parri R, Boni L et al.
Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas.
Gastrointestinal Endoscopy, 46:124-130, 1997
■
Tonini GP, Boni L, Pession A et al.
MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the italian experience with 295
children.
Journal of Clinical Oncology, 15(1):85-93, 1997
■
Colleoni M, Biasin M, Boni L et al.
Prognostic value of proliferating cell nuclear antigen (PCNA) expression in unresectable hepatocellular carcinoma.
International Journal of Oncology, IN PRESS
■
Byrne J, Cama A, Reilly M, Vigliarolo M, Levato L, Boni L, Lavia N, Andreussi L
Multigeneration maternal transmission in Italian families with neural tube defects.
Am J Med Genet, 66(3):303-310, 1996
Page 9 / 12 - Curriculum vitae of
Luca Boni
November, 2014
■
Colleoni M, Boni L, Vicario G et al.
A dose-escalating study of carboplatin combined with vinorelbine in non-small-cell lung cancer.
Oncology, 53(5):364-368, 1996
■
Italian Cooperative Research Group on Palliative Medicine
Classification and staging of terminal cancer patients: rationale and objectives of a multicentre cohort prospective study and methods used.
Support Care Cancer, 4:56-60, 1996
■
Colleoni M, Boni L, Nelli P, Pancheri P, Vicario G, Sgarbossa G, Manente P
Feasibility and tolerance of cisplatini and fluorouracil infusion in elderly patients with squamous cell carcinoma.
Oncology Reports, 2:801-803, 1995
■
Colleoni M, Biasin MR, Boni L, Nelli P, Manente P, Gaion F, Perasole A, Infantolino D
Evaluation of KI-67 expression as a prognostic feature in hepatocellular carcinoma in cirrhosis.
European Journal of Cancer, 31A(9):1547-1548, 1995
■
Colleoni M, Boni L, Calabrò F, Manente P, Nelli P, Gaion F, Pancheri F, Sartori F
Prognostic evaluation of patients submitted to surgery for malignant pleural mesothelioma.
International Journal of Oncology, 6:1261-1265, 1995
■
Iliceto S, Scrutinio D, Bruzzi P, D’Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, Rizzon P
Effects of L-Carnitine administration on left ventricular remodelling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia
Digitalizzata Infarto Miocardico (CEDIM) trial.
Journal of American College of Cardiology, 26(2):380-387, 1995
■
Scrutinio D, Lagioia R, Ricci A, Clemente M, Boni L, Rizzon P
Prediction of mortality in mild to moderately symptomatic patients with left ventricular dysfunction. The role of the New York Heart
Association classification, cardiopulmonary exercise testing, two-dimensional echocardiography and Holter monitoring.
European Heart Journal, 15(8):1089-1095, 1994
■
Viscoli C, Bruzzi P, Castagnola E, Boni L et al.
Factors associated with bacteraemia in febrile, granulocytopenic cancer patients.
European Journal of Cancer, 30(4):430-437, 1994
■
Dini G, Boni L, Abla O et al.
Allogenic bone marrow transplantation in children with acute myelogenous leukemia in first remission.
Bone Marrow Transplant, 13(6):771-6, 1994
■
Garrè ML, Haupt R, Boni L et al.
Health status of long term survivors after cancer in childhood: results of an uni-institutional study in Italy.
The American Journal of Pediatric Hematology/Oncology, 16(2): 143-152, 1994
■
Iliceto S, D'Ambrosio G, Scrutinio D, Marangelli V, Boni L, Rizzon P
A digital network for long-distance echocardiographic image and data transmission in clinical trials: the CEDIM study experience.
Journal of American Society of Echocardiography, 6(6):583-592, 1993
■
Garaventa A, De Bernardi B, Pianca C, Boni L et al.
Localized but unresectable neuroblastoma: treatment and outcome of 145 cases.
Journal of Clinical Oncology, 11(9):1770-1779, 1993
■
Colleoni M, Bajetta E, Nelli P, Boni L et al.
Prognostic factors in patients affected by hepatocellular carcinoma treated with systemic chemotherapy: the experience of the National
Cancer Institute of Milan.
Annals of Oncology, 4:489-493, 1993
■
De Bernardi B, Carli M, Casale F, Corciulo P, Boni L et al
Standard-Dose and High-Dose Peptichemio and Cisplatin in Children With Disseminated Poor-Risk Neuroblastoma: Two Studies by the
Italian Cooperative Group for Neuroblastoma
Journal of Clinical Oncology, 10(12):1870-1878, 1992
■
De Bernardi B, Pianca C, Boni L et al.
Disseminated Neuroblastoma (Stage IV and IV-S) in the First Year of Life
Cancer, 70(6):1625-1633, 1992
Page 10 / 12 - Curriculum vitae of
Luca Boni
November, 2014
■
Dini G, Lanino E, Garaventa A, Rogers D, Dallorso S, Viscoli C, Castagnola E, Manno G, Brisigotti M, Rosanda C, Boni L et al
Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases.
Journal of Clinical Oncology, 9:962-969, 1991
■
Dini G, Lanino E, Garaventa A, Boni L et al.
Unpurged ABMT for neuroblastoma: AIEOP-BMT experience.
Bone Marrow Transplantation, (7 Suppl 2):92, 1991
■
Lanino E, Boni L, Corciulo P, De Bernardi B
Did BMT change the clinical course of neuroblastoma?
BMT, 7(3):114-117, 1991
■
Dini G, Lanino E, Garaventa A, Paolucci P, Boni L et al.
Unpurged autologous bone marrow transplantation for neuroblastoma: the AIEOP-BMT Group experience.
BMT, 7(3):109-111, 1991
■
Dini G, Abla O, Uderzo C, Boni L et al.
Allogeneic bone marrow transplantation in children with ANL: italian experience.
BMT, 7(3):75-77, 1991
■
Viscoli C, Castagnola E, Moroni C, Boni L et al.
Early infectious complications in children undergoing bone marrow transplantation.
BMT, 7(2):42-47, 1991
■
Viscoli C, Dudley M, Boni L et al.
Serum concetrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation.
J Antimicrob Chemother, 27(C):113-120, 1991
■
Viscoli C, Moroni C, Boni L et al.
Ceftazidime plus amikacin or ceftazidime plus vancomycin as empiric therapy in febrile neutropenic children with cancer: a prospective,
randomized clinical study.
Rev Infect Dis, 13:397-404, 1991
■
Gazzolo D, Novelli M, Bocchino G, Esposito V, Boni L, Bruschettini PL
Foetal monitoring in hypertensive pregnancies by computerized processing.
J Clin Exp Hypertension, (8), 1990
■
Dallorso S, Lanino E, Dini G, Garaventa A, Boni L et al.
Regimen related toxicity in children undergoing autologous bone marrow transplantation (ABMT).
Exp Hematol, 18(6):669, 1990
■
EORTC International Antimicrobial Therapy Cooperative Group.
Gram-positive bacteraemia in granulocytopenic cancer patients.
Eur J Cancer, 26(5):569-574, 1990
■
Corrias MV, Cornaglia-Ferraris P, Di Martino D, Stenger AM, Lanino E, Boni L, Tonini GP
Expression of multiple drug resistance gene, MDR1, and N-myc oncogene in an italian population of human neuroblastoma patients.
Anticancer Research, 10:897-902, 1990
■
Dini G, Dallorso S, Porlezza M, Boni L et al.
Platelet support in children undergoing autologous BMT: experience on 113 cases treated in a single institution.
BMT, 5(2):148, 1990
■
Dini G, Garaventa A, Lanino E, Dallorso S, Boni L et al.
Myeloablative therapy and unpurged autologous BMT in Neuroblastoma: report of 26 patients with a minimum follow-up of 24 months from
the ABMT.
BMT, 5(2):89, 1990
■
Dini G, Trasino A, Lucigrai G, Lanino E, Dallorso S, Garaventa A, Boni L et al.
Total body irradiation (TBI) in patients aged less thn 4 years: ketamine sedation.
BMT, 3(1):296, 1988
Page 11 / 12 - Curriculum vitae of
Luca Boni
November, 2014
■
Dini G, Amici A, Boni L, Cornelli P, Dallorso S, De Laurentis C, Garaventa A, De Bernardi B
Disseminated neuroblastoma: preliminary results of AIEOP NB-85 protocol.
BMT, 3(1):88, 1988
■
Viscoli C, Garaventa A, Boni L, Melodia A, Dini G, Cuneo R, Rogers D, De Bernardi B et al.
Role of Broviac catheters in infections in children with cancer.
Pediatr Infect Dis J, 7:556-560, 1988
Page 12 / 12 - Curriculum vitae of
Luca Boni
November, 2014